Clinical Trial Update: ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 study of ADX48621 for Levodopa-induced dyskinesia in Parkinson's disease has completed. Sponsor: Addex Pharma S.A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• ADX48621

Snippet

Sponsor: Addex Pharma S.A. | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED